##### Table of Contents



SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 FORM 10-Q
 (Mark One)
 þ
    
    Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
 For the quarterly period ended September 30, 2007,
 or
 o
    
    Transition Period Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
 For the Transition Period From  to  .
 Commission file number 0-19591
 IDM PHARMA, INC.
  Delaware
    
    33-0245076(State or other jurisdiction of incorporation or 
organization)
    
    (I.R.S. Employer Identification No.)
 
 (Registrants telephone number, including area code)
 þ o
  o o þ
 o þ




---



##### 



IDM PHARMA, INC.
QUARTERLY REPORT
FORM 10-Q
   PART I. FINANCIAL INFORMATIONITEM 1. Financial StatementsCondensed Consolidated Balance Sheets as of September 30, 2007 (unaudited) and December
31, 2006
    
    
    3Condensed Consolidated Statements of Operations for the Three and Nine Months Ended
September 30, 2007 and 2006 (unaudited)
    
    
    4Condensed Consolidated Statements of Cash Flows for the Nine Months ended September 30,
2007 and 2006 (unaudited)
    
    
    5Notes to Condensed Consolidated Financial Statements (unaudited)
    
    
    6ITEM 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
    
    
    21ITEM 3. Quantitative and Qualitative Disclosures about Market Risk
    
    
    31ITEM 4. Controls and Procedures
    
    
    32PART II. OTHER INFORMATIONITEM 1. Legal Proceedings
    
    
    34ITEM 1A. Risk Factors
    
    
    34ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds
    
    
    *ITEM 3. Defaults upon Senior Securities
    
    
    *ITEM 4. Submission of Matters to a Vote of Security Holders
    
    
    *ITEM 5. Other Information
    
    
    *ITEM 6. Exhibits
    
    
    49SIGNATURES
    
    
    51EXHIBIT 10.65EXHIBIT 31.1EXHIBIT 31.2EXHIBIT 32.1
  
 *
    
    No information provided due to inapplicability of item. 2




---



##### Table of Contents



PART I. FINANCIAL INFORMATION
 
 ITEM I. FINANCIAL STATEMENTS
 IDM PHARMA, INC.
 
 CONDENSED CONSOLIDATED BALANCE SHEETS
 September 30,
    
    
    December 31,2007
    
    
    2006(unaudited)ASSETSCurrent assets:Cash and cash equivalents
    
    $
    33,183,000
    
    
    $
    10,181,000Related party accounts receivable
    
    
    3,450,000
    
    
    
    3,353,000Accounts receivable
    
    
    120,000
    
    
    
    39,000Research and development tax credit, current portion
    
    
    812,000
    
    
    
    201,000Prepaid expenses and other current assets
    
    
    805,000
    
    
    
    1,380,000Total current assets
    
    
    38,370,000
    
    
    
    15,154,000Property and equipment, net
    
    
    1,205,000
    
    
    
    1,711,000Patents, trademarks and other licenses, net
    
    
    3,188,000
    
    
    
    3,323,000Goodwill
    
    
    2,812,000
    
    
    
    2,812,000Research and development tax credit, less current portion
    
    
    704,000
    
    
    
    1,300,000Other long-term assets
    
    
    88,000
    
    
    
    82,000Total assets
    
    $
    46,367,000
    
    
    $
    24,382,000LIABILITIES AND STOCKHOLDERS EQUITYCurrent liabilities:Accounts payable and accrued liabilities
    
    $
    5,425,000
    
    
    $
    4,935,000Common stock warrants
    
    
    1,506,000
    
    
    
    Accrued payroll and related expenses
    
    
    2,556,000
    
    
    
    1,251,000Related party deferred revenues, current portion
    
    
    1,193,000
    
    
    
    769,000Other current liabilities
    
    
    3,074,000
    
    
    
    3,681,000Total current liabilities
    
    
    13,754,000
    
    
    
    10,636,000Long-term debt, less current portion
    
    
    532,000
    
    
    
    505,000Related party deferred revenues, less current portion
    
    
    2,173,000
    
    
    
    2,593,000Other non-current liabilities
    
    
    519,000
    
    
    
    452,000Total liabilities
    
    
    16,978,000
    
    
    
    14,186,000Stockholders equity:Preferred stock, $0.01 par value, 10,000,000 shares authorized and no shares issued and
outstanding at September 30, 2007 and December 31, 2006
    
    
    
    
    
    
    Common stock, $0.01 par value, 55,000,000 shares authorized at September 30, 2007 and
December 31, 2006 and 25,148,380 and 13,401,071 shares issued and outstanding
at September 30, 2007 and December 31, 2006, respectively
    
    
    251,000
    
    
    
    134,000Additional paid-in capital
    
    
    204,694,000
    
    
    
    171,892,000Accumulated other comprehensive income
    
    
    18,339,000
    
    
    
    16,701,000Accumulated deficit
    
    
    (193,895,000
    )
    
    
    (178,531,000
    )Total stockholders equity
    
    
    29,389,000
    
    
    
    10,196,000$
    46,367,000
    
    
    $
    24,382,000
 See accompanying notes.
 3




---



##### Table of Contents



IDM PHARMA, INC.
 
 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
 (unaudited)
 Three months ended September 30,
    
    Nine months ended September 30,2007
    
    2006
    
    2007
    
    2006Revenues:Research grants and contract revenue
    
    $
    
    
    
    $
    
    
    
    $
    55,000
    
    
    $
    68,000Related party revenue
    
    
    3,113,000
    
    
    
    3,012,000
    
    
    
    8,994,000
    
    
    
    8,228,000License fees, milestones and other revenues
    
    
    10,000
    
    
    
    16,000
    
    
    
    30,000
    
    
    
    32,000Total revenues
    
    
    3,123,000
    
    
    
    3,028,000
    
    
    
    9,079,000
    
    
    
    8,328,000Costs and expenses:Research and development
    
    
    6,377,000
    
    
    
    5,271,000
    
    
    
    17,032,000
    
    
    
    17,032,000Impairment of assets
    
    
    52,000
    
    
    
    144,000
    
    
    
    95,000
    
    
    
    497,000Selling and marketing
    
    
    246,000
    
    
    
    234,000
    
    
    
    448,000
    
    
    
    397,000General and administrative
    
    
    2,477,000
    
    
    
    1,563,000
    
    
    
    9,216,000
    
    
    
    6,817,000Total costs and expenses
    
    
    9,152,000
    
    
    
    7,212,000
    
    
    
    26,791,000
    
    
    
    24,743,000Loss from operations
    
    
    (6,029,000
    )
    
    
    (4,184,000
    )
    
    
    (17,712,000
    )
    
    
    (16,415,000
    )Interest income
    
    
    422,000
    
    
    
    118,000
    
    
    
    758,000
    
    
    
    427,000Interest expense
    
    
    2,719,000
    
    
    
    
    
    
    
    2,825,000
    
    
    
    Other income (expenses), net
    
    
    (23,000
    )
    
    
    49,000
    
    
    
    (23,000
    )
    
    
    Foreign exchange gain (loss)
    
    
    (837,000
    )
    
    
    165,000
    
    
    
    (1,299,000
    )
    
    
    (1,698,000
    )Loss before income tax benefit
    
    
    (3,748,000
    )
    
    
    (3,852,000
    )
    
    
    (15,451,000
    )
    
    
    (17,686,000
    )Income tax benefit (expense)
    
    
    (5,000
    )
    
    
    
    
    
    
    87,000
    
    
    
    179,000Net loss
    
    $
    (3,753,000
    )
    
    $
    (3,852,000
    )
    
    $
    (15,364,000
    )
    
    $
    (17,507,000
    )Weighted average number of shares outstanding
    
    
    25,146,206
    
    
    
    13,398,474
    
    
    
    19,703,272
    
    
    
    13,354,184Basic and diluted loss per share
    
    $
    (0.15
    )
    
    $
    (0.29
    )
    
    $
    (0.78
    )
    
    $
    (1.31
    )Comprehensive loss:Net loss
    
    $
    (3,753,000
    )
    
    $
    (3,852,000
    )
    
    $
    (15,364,000
    )
    
    $
    (17,507,000
    )Other comprehensive gain (loss)
    
    
    1,094,000
    
    
    
    (224,000
    )
    
    
    1,638,000
    
    
    
    2,388,000$
    (2,659,000
    )
    
    $
    (4,076,000
    )
    
    $
    (13,726,000
    )
    
    $
    (15,119,000
    )
 See accompanying notes.
 4




---



##### Table of Contents



IDM PHARMA, INC.
 
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 (unaudited)
 Nine months ended September 30,2007
    
    
    2006Operating activitiesNet loss
    
    $
    (15,364,000
    )
    
    $
    (17,507,000
    )Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense
    
    
    1,366,000
    
    
    
    580,000Change in fair value of common stock warrants
    
    
    (2,825,000
    )
    
    
    Depreciation and amortization
    
    
    845,000
    
    
    
    998,000Impairment of patents and licenses
    
    
    95,000
    
    
    
    491,000Impairment of property and equipment
    
    
    315,000
    
    
    
    Foreign exchange loss
    
    
    1,500,000
    
    
    
    1,680,000Change in operating assets and liabilities:Related party accounts receivable (sanofi-aventis)
    
    
    155,000
    
    
    
    (644,000
    )Accounts receivable
    
    
    (79,000
    )
    
    
    820,000Prepaid expenses and other current assets
    
    
    633,000
    
    
    
    793,000Research and development tax credit receivable
    
    
    95,000
    
    
    
    336,000Other long-term assets
    
    
    
    
    
    
    25,000Accounts payable and accrued liabilities
    
    
    18,000
    
    
    
    121,000Accrued payroll and related expenses
    
    
    1,192,000
    
    
    
    (1,592,000
    )Related party deferred revenues (sanofi-aventis)
    
    
    (243,000
    )
    
    
    (389,000
    )Other liabilities
    
    
    (1,630,000
    )
    
    
    144,000Net cash used in operating activities
    
    
    (13,927,000
    )
    
    
    (14,144,000
    )Investing activitiesPurchase of property and equipment
    
    
    (197,000
    )
    
    
    (188,000
    )Patents, trademarks and other licenses
    
    
    (140,000
    )
    
    
    (183,000
    )Net cash used in investing activities
    
    
    (337,000
    )
    
    
    (371,000
    )Financing activitiesNet proceeds from issuance of common stock
    
    
    36,007,000
    
    
    
    49,000Net cash provided by financing activities
    
    
    36,007,000
    
    
    
    49,000Effect of exchange rate on cash and cash equivalents
    
    
    1,259,000
    
    
    
    738,000Increase (decrease) in cash and cash equivalents
    
    
    23,002,000
    
    
    
    (13,728,000
    )Cash and cash equivalents at beginning of year
    
    
    10,181,000
    
    
    
    26,702,000Cash and cash equivalents at end of period
    
    $
    33,183,000
    
    
    $
    12,974,000
 See accompanying notes.
 5




---



##### Table of Contents



IDM PHARMA, INC.
 
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 (unaudited)
 September 30, 2007
 1. The Company
  tm)
 tm)
     6




---



##### Table of Contents



®
  ® ®
  2. Basis of Presentation
    7




---



##### Table of Contents



3. Recent Operating Results and Liquidity
    4. Summary of Significant Accounting Policies
  Foreign Currency Translation
    8




---



##### Table of Contents



Reporting Comprehensive Income
 Major customer and concentration of credit risk
   Revenue recognition
 Revenue
Recognition, Revenue Arrangements with Multiple
Deliverables.
    9




---



##### Table of Contents



Research and development expenses and related tax credit
    Patents, trademarks and licenses
 Accounting for the Impairment or
Disposal of Long-Lived Assets
  10




---



##### Table of Contents



Impairment of long lived assets
   Segment Information
  Goodwill
 Goodwill and Other Intangible Assets
 Net Loss Per Share
 Earnings
per Share.
 11




---



##### Table of Contents



September 30, 2007
    
    
    September 30, 2006Options outstanding
    
    
    2,069,421
    
    
    
    1,061,633Restricted stock awards
    
    
    202,141
    
    
    
    42,141Warrants outstanding
    
    
    3,377,412
    
    
    
    211,882Reserved pursuant to option liquidity agreements
    
    
    372,868
    
    
    
    389,031Reserved pursuant to put/call agreements
    
    
    
    
    
    
    52,049Total
    
    
    6,021,842
    
    
    
    1,756,736
 Share-Based Compensation Plans
 Description of Share-Based Compensation Plans
      12




---



##### Table of Contents



Adoption of SFAS No. 123(R)
 Share-Based Payment
  September 30, 2007
    
    September 30, 2006Research and development
    
    $
    220,000
    
    
    $
    101,000General and administrative
    
    
    1,137,000
    
    
    
    490,000Sales and marketing
    
    
    9,000
    
    
    
    2,000Total stock-based compensation expense
    
    $
    1,366,000
    
    
    $
    593,000
  Weighted
    
    
    Weighted AverageAverage
    
    
    Remaining
    
    
    AggregateExercise
    
    
    Contractual Term
    
    
    IntrinsicShares
    
    
    Price
    
    
    (years)
    
    
    ValueOptions outstanding, December 31, 2006
    
    
    2,272,655
    
    
    $
    9.84Granted
    
    
    810,700
    
    
    $
    4.96Exercised
    
    
    (4,130
    )
    
    $
    3.32Cancelled, forfeited or expired
    
    
    (636,936
    )
    
    $
    5.33Options outstanding, September 30, 2007
    
    
    2,442,289
    
    
    $
    10.77
    
    
    
    7.43
    
    
    $
    Options exercisable, September 30, 2007
    
    
    1,179,752
    
    
    $
    15.85
    
    
    
    5.86
    
    
    $
    
  Performance-Based Stock Options and Awards
 Accounting for Equity Instruments That Are Issued to Other
Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services.
 13




---



##### Table of Contents



5. Sale of Common Stock and Warrants
      14




---



##### Table of Contents



Accounting for Derivative Financial Instruments Indexed To, and
Potentially Settled In, a Companys Own Stock,
  6. Research and Development and Other Agreements
 Novartis -Jenner
    15




---



##### Table of Contents



Agreement with sanofi-aventis (Related Party)
    Three months ended
    
    Nine months endedSeptember 30,
    
    September 30,2007
    
    2006
    
    2007
    
    2006Amortization of upfront fee
    
    $
    60,000
    
    
    $
    56,000
    
    
    $
    177,000
    
    
    $
    164,000Amortization of phase 1 milestone payment
    
    
    71,000
    
    
    
    66,000
    
    
    
    210,000
    
    
    
    195,000Amortization of initial R&D expenses from 1999 to 2001
    
    
    58,000
    
    
    
    53,000
    
    
    
    169,000
    
    
    
    156,000Reimbursement of current R&D expenses
    
    
    2,924,000
    
    
    
    2,837,000
    
    
    
    8,438,000
    
    
    
    7,713,000Total revenues
    
    $
    3,113,000
    
    
    $
    3,012,000
    
    
    $
    8,994,000
    
    
    $
    8,228,000
   Medarex (Related Party)
  16




---



##### Table of Contents



Cambridge Labs
     7. Commitments
 Obligations under collaboration, licensing and contract research organization agreements
  Commitment with Biotecnol
  Commitment with Accovion
  17




---



##### Table of Contents



PEA Shares
  8 Government Research Funding
  9. Restructuring and Severance Related Charges
 Accounting for Costs Associated with Exit or Disposal Activities
  18




---



##### Table of Contents



10. FIN 48 Uncertain Tax Positions
 Accounting for Uncertainty in Income Taxes, an interpretation of SFAS No. 109, Accounting
for Income Taxes
    19




---



##### Table of Contents



New Accounting Standards Not Yet Adopted
 Fair Value Measurements
 The Fair Value Option for Financial Assets and
Financial Liabilities
 20




---



##### Table of Contents



ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 This discussion and analysis should be read in conjunction with our financial statements and
accompanying notes included in this report and our 2006 audited financial statements and notes
thereto included in our Form 10-K filed with the Securities and Exchange Commission on April 2,
2007.
 Operating results for the three and nine months ended September 30, 2007 are not necessarily
indicative of results that may occur in future periods.
 Except for the historical information contained herein, the following discussion contains
forward-looking statements that involve risks and uncertainties. When used herein, the words
believe, anticipate, expect, estimate and similar expressions are intended to identify such
forward-looking statements. There can be no assurance that these statements will prove to be
correct. Our actual results could differ materially from those discussed here. Factors that could
cause or contribute to such differences include, but are not limited to, those discussed in this
report. We undertake no obligation to update any of the forward-looking statements contained herein
to reflect any future events or developments.
 Overview
  in vivo
    21




---



##### Table of Contents



22




---



##### Table of Contents



23




---



##### Table of Contents



Results of Operations for the Three Months Ended September 30, 2007 and 2006
 Revenues.
   Research and Development Expense and Impairment of Patents and Licenses.
    Selling and Marketing Expenses.
 24




---



##### Table of Contents



General and Administrative Expenses.
 Interest Income or Expense, Net.
 Foreign Exchange Gain or Loss.
 Income Tax Benefit or Liability.
  Net Loss.
 Results of Operations for the Nine Months Ended September 30, 2007 and 2006
 Revenues.
   25




---



##### Table of Contents



Research and Development Expenses and Impairment of Licenses.
    Selling and Marketing Expenses.
 General and Administrative Expenses.
 Interest Income or Expense, Net.
 Foreign Exchange Gain or Loss.
 Income Tax Benefit.
  26




---



##### Table of Contents



Net Loss.
 Liquidity and Capital Resources
       27




---



##### Table of Contents



28




---



##### Table of Contents



Off-Balance Sheet Arrangements
  
    
    any obligations under a guarantee contract;
    
    a retained or contingent interest in assets transferred to an unconsolidated entity or
similar arrangement that serves as credit, liquidity or market risk support for such assets;
    
    any obligation under a derivative instrument that is both indexed to our stock and
classified in shareholders equity, or not reflected, in our statement of financial
position; or
    
    any obligation, including a contingent obligation, arising out of a variable interest, in
an unconsolidated entity that is held by, and material to, us, where such entity provides
financing, liquidity, market risk or credit risk support to us, or engages in leasing,
hedging or research and development services with us.
 Trends
   29




---



##### Table of Contents



30




---



##### Table of Contents



ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
  31




---



##### Table of Contents



ITEM 4. CONTROLS AND PROCEDURES
      
    
    Consolidate operating and financial reporting locations and structure;
    
    Implement additional review and approval procedures over accruals;
 32




---



##### Table of Contents




    
    Formalize process and documentation related to financial statement close and
consolidation review, including face-to-face meeting of all members of our financial staff
involved in preparation of financial statements and a review of those financial statements
by the entire staff as a group;
    
    Formalize and enhance documentation, oversight and review procedures related to
accounting records of our foreign subsidiary to ensure compliance with U.S. generally
accepted accounting principles;
    
    Supplement internal staff expertise by consulting with independent, third party experts
regarding accounting treatment of unusual or non-routine transactions, and the impact of the
adoption of new accounting pronouncements, when and if necessary;
    
    Review and make appropriate staffing adjustments at all company locations to enhance
accounting expertise;
    
    Revise and enhance the review process for unusual and acquisition related transactions;
    
    Improve training for, and integration and communication among, accounting and financial
staff; and
    
    In May 2007, we hired a full-time experienced Chief Financial Officer.
    
    During the third quarter of 2007, we hired additional full-time experienced accounting
and finance staff, including a controller.(b)
    
    Changes in Internal Control Over Financial Reporting
  33




---



##### Table of Contents



PART II. OTHER INFORMATION
 
 ITEM 1. LEGAL PROCEEDINGS
  
 ITEM 1A. RISK FACTORS
 We wish to caution readers that the following important factors, among others, in some
cases have affected our results and in the future could cause our actual results and needs to vary
materially from forward-looking statements made from time to time by us on the basis of
managements then-current expectations. The business in which we are engaged is in a rapidly
changing and competitive market and involves a high degree of risk, and accuracy with respect to
forward-looking projections is difficult.
 The Company has marked with an asterisk those risk factors that reflect changes from the
risk factors included in the Companys Annual Report on Form 10-K filed with the SEC.
 *Our lead product candidate, L-MTP-PE, may never obtain regulatory approval.
   34




---



##### Table of Contents



*Even if we receive regulatory approval for L-MTP-PE, we may not be able to commercialize it
immediately or market it successfully.
    Even if we obtain regulatory approval for our products, we may be required to perform additional
clinical trials or change the labeling of our products if we or others identify side effects after
our products are on the market, which could harm sales of the affected products.
  
    
    regulatory approval may be withdrawn;
 35




---



##### Table of Contents




    
    reformulation of our products, additional clinical trials, changes in labeling of
our products or changes to or re-certifications of our manufacturing facilities may
be required;
    
    sales of the affected products may drop significantly;
    
    our reputation in the marketplace may suffer; and
    
    lawsuits, including costly and lengthy class action suits, may be brought against us.
  *Our substantial additional capital requirements and potentially limited access to financing may
harm our ability to develop products and fund our operations, and if we do not obtain additional
funding we may be required to sell our assets or our company, or dissolve and liquidate all of our
assets.
  
    
    whether we are able to secure additional financing on favorable terms, or at all;
    
    the costs associated with, and the success of, obtaining marketing approval and,
as applicable, pricing approval, for L-MTP-PE for the treatment of osteosarcoma
in the United States, Europe and other jurisdictions and the timing of any such
approval;
    
    the success or failure of the product launch and commercialization of L-MTP-PE;
    
    the costs associated with the launch and the commercialization of L-MTP-PE in the
United States, Europe and other jurisdictions upon obtaining marketing approval;
    
    the costs associated with our clinical trials for our product candidates,
including our melanoma and lung cancer vaccine candidates;
    
    progress with other preclinical testing and clinical trials in the future;
    
    our ability to establish and maintain collaboration and license agreements and
any government contracts and grants;
    
    the actual revenue we receive under our collaboration and license agreements;
    
    the actual costs we incur under our collaboration agreements;
    
    the time and costs involved in obtaining regulatory approvals for our products;
    
    the costs involved in filing, prosecuting, enforcing and defending patent claims
and any other proprietary rights;
    
    competing technological and market developments; and
    
    the magnitude of our immunotherapeutic product discovery and development programs.
 36




---



##### Table of Contents



*The process of developing immunotherapeutic products requires significant research and
development, preclinical testing and clinical trials, all of which are extremely expensive and
time-consuming and may not result in a commercial product.
  
    
    the results of preclinical studies may be inconclusive, or they may
not be indicative of results that will be obtained in human clinical
trials;
    
    after reviewing test results, we may abandon projects that we might
previously have believed to be promising;
    
    after reviewing test results, our collaborators may abandon projects
that we might believe are still promising and we would either have to
bear the operating expenses and capital requirements of continued
development of our therapeutic cancer vaccines or abandon the projects
outright;
    
    we, our collaborators or government regulators may suspend or
terminate clinical trials if the participating subjects or patients
are being exposed to unacceptable health risks;
    
    clinical trials may be delayed as a result of difficulties in
identifying and enrolling patients who meet trial eligibility
criteria;
 37




---



##### Table of Contents




    
    safety and efficacy results attained in early human clinical trials
may not be indicative of results that are obtained in later clinical
trials; and
    
    our product candidates may not have the desired effects or may have
undesirable side effects that preclude regulatory approval or limit
their commercial use, if approved.
  *Our principal source of revenues and cash receipts currently is a collaboration agreement under
which our partner has limited obligations.
  *Our revenues and operating results are likely to fluctuate.
  
    
    any payments from sanofi-aventis and any other current or future collaborative partners;
    
    any government and European Union grants and contracts; and
    
    investment income.
   38




---



##### Table of Contents



*Our history of operating losses and our expectation of continuing losses may hurt our ability to
reach profitability or continue operations.
  *If we lose our key management personnel or are unable to attract and retain qualified personnel,
it could delay or hurt our research and product development efforts.
  *Unexpected or undesirable side effects or other characteristics of our products and technology may
delay or otherwise hurt the development of our drug candidates, or may expose us to significant
liability that could cause us to incur significant costs.
  39




---



##### Table of Contents



Adverse publicity regarding the safety or side effects of the technology approach or products of
others could negatively impact us and cause the price of our common stock to decline.
  *Our treatment approach may not prove effective.
  
    
    the targeted antigens are not sufficiently different from those normal cells to cause an immune reaction;
    
    the tumor cells do not express the targeted antigen or other target structures at all or in sufficient
quantities to be recognized by immune system cells, such as T cells or macrophages;
    
    the immune response stimulated by the immunotherapeutic agent is not strong enough to destroy all of the
cancer cells; or
    
    cancer cells may, through various mechanisms, escape an immune response.
  If we cannot enter into and maintain strategic collaborations on acceptable terms in the future, we
may not be able to develop products in markets where it would be too costly or complex to do so on
our own.
  40




---



##### Table of Contents



If our collaboration or license arrangements are unsuccessful, our revenues and product development
may be limited.
  
    
    collaborations and licensee arrangements may be terminated, in which
case we will experience increased operating expenses and capital
requirements if we elect to pursue further development of the product
candidate;
    
    collaborators and licensees may delay clinical trials and prolong
clinical development, under-fund a clinical trial program, stop a
clinical trial or abandon a product candidate;
    
    expected revenue might not be generated because milestones may not be
achieved and product candidates may not be developed;
    
    collaborators and licensees could independently develop, or develop
with third parties, products that could compete with our future
products;
    
    the terms of our contracts with current or future collaborators and
licensees may not be favorable to us in the future;
    
    a collaborator or licensee with marketing and distribution rights to
one or more of our products may not commit enough resources to the
marketing and distribution of our products, limiting our potential
revenues from the commercialization of a product; and
    
    disputes may arise delaying or terminating the research, development
or commercialization of our product candidates, or result in
significant and costly litigation or arbitration.
 We may not be able to license technology necessary to develop products.
  *Our supplies of certain materials necessary to our business may be limited and key raw materials
of desired quantity and quality may be difficult to obtain.
   41




---



##### Table of Contents



*If we and/or our collaborators cannot cost-effectively manufacture our immunotherapeutic product
candidates in commercial quantities or for clinical trials in compliance with regulatory
requirements, we and/or our collaborators may not be able to successfully commercialize the
products.
   
    
    non-compliance by these third parties with regulatory and quality control standards;
 42




---



##### Table of Contents




    
    breach by these third parties of their agreements with us; and
    
    termination or non-renewal of these agreements for reasons beyond our control.
    We are subject to extensive and uncertain government regulation and we may not be able to obtain
necessary regulatory approvals.
  
    
    fines and penalties;
    
    injunctions;
    
    seizure of products;
    
    total or partial suspension of product marketing;
    
    failure of a regulatory agency to grant marketing authorization;
    
    withdrawal of marketing approvals; and
    
    criminal prosecution.
  43




---



##### Table of Contents



We may not be able to commercialize products under development by us if those products infringe
claims in existing patents or patents that have not yet issued, and this would materially harm our
ability to operate.
  Our failure to obtain issued patents and, consequently, to protect our proprietary technology,
could hurt our competitive position.
  
    
    the pending patent applications we have filed or to which we have exclusive rights
may not result in issued patents or may take longer than we expect to result in
issued patents;
    
    the allowed claims of any patents that issue may not provide meaningful protection;
    
    we may be unable to develop additional proprietary technologies that are patentable;
    
    the patents licensed or issued to us may not provide a competitive advantage;
    
    other companies may challenge patents licensed or issued to us;
    
    disputes may arise regarding inventions and corresponding ownership rights in
inventions and know-how resulting from the joint creation or use of our
intellectual property and our respective licensors or collaborators; and
    
    other companies may design around the technologies patented by us.
 44




---



##### Table of Contents



If we are unable to compete effectively in the highly competitive biotechnology industry, our
business will fail.
     Litigation regarding intellectual property rights owned or used by us may be costly and
time-consuming.
    
    
    assert against others or defend ourselves against claims of infringement;
    
    enforce patents owned by, or licensed to us from another party;
    
    protect our trade secrets or know-how; or
    
    determine the enforceability, scope and validity of our proprietary rights or those of others.
 45




---



##### Table of Contents



If we are unable to protect our trade secrets, we may be unable to protect from competitors our
interests in proprietary know-how that is not patentable or for which we have elected not to seek
patent protection.
  The U.S. government will fund some of our programs and, therefore, the U.S. government may have
rights to certain of our technology and could require us to grant licenses of our inventions to
third parties.
 .
 Successful commercialization of our future products will depend on our ability to gain acceptance
by the medical community.
  
    
    the extent to which our therapeutic product candidates are
demonstrated to be safe and effective in clinical trials;
    
    convenience and ease of administration;
    
    the success of sales, marketing and public relations efforts;
    
    the availability of alternative treatments;
    
    competitive pricing;
    
    the reimbursement policies of governments and other third parties; and
    
    garnering support from well respected external advocates.
  *We may experience difficulties managing our growth, which could adversely affect our results of
operations.
  46




---



##### Table of Contents




    
    train, manage, motivate and retain a growing employee base, particularly given our operations in
both California and France;
    
    accurately forecast demand for, and revenues from, our product candidates, particularly L-MTP-PE; and
    
    expand existing operational, financial and management information
systems to support our development and planned commercialization
activities and the multiple locations of our offices.
  *Our use of hazardous materials could expose us to significant costs.
   Our financial results may be adversely affected by fluctuations in foreign currency exchange rates.
  *The volatility of the price of our common stock may adversely affect stockholders.
  
    
    The development and regulatory status of our product candidates, particularly L-MTP-PE;
    
    whether we are able to secure additional financing on favorable terms, or at all;
    
    announcements of technological innovations or new commercial immunotherapeutic products by us or
others;
 47




---



##### Table of Contents




    
    governmental regulation that affects the biotechnology and pharmaceutical industries in general or
us in particular;
    
    developments in patent or other proprietary rights by us;
    
    receipt of funding by us under collaboration and license agreements and government grants;
    
    developments in, or termination of, our relationships with our collaborators and licensees;
    
    public concern as to the clinical results and/or the safety of drugs developed by us or others; and
    
    announcements related to the sale of our common stock or other securities.
  *Our principal stockholders, executive officers and directors own a significant percentage of
shares of our common stock and, as a result, the trading price for shares of our common stock may
be depressed. These stockholders may make decisions that may be adverse to your interests.
   Future sales of shares of our common stock may cause the market price of your shares to decline.
  48




---



##### Table of Contents



ITEM 6. EXHIBITS
 ExhibitNumber
    
    Document Description3.1
    
    Amended and Restated Certificate of Incorporation filed with the Secretary of State of
Delaware on December 2, 1991.(1)3.2
    
    Certificate of Designation of Series A Junior Participating Preferred Stock filed with the
Secretary of State of Delaware on April 2, 1993.(2)3.3
    
    Certificate of Amendment of Amended and Restated Certificate of Incorporation filed with the
Secretary of State of Delaware on July 5, 1995.(3)3.4
    
    Certificate of Increase of Series A Junior Participating Preferred Stock filed with the
Secretary of State of Delaware on July 5, 1995.3.5
    
    Certificate of Amendment of Amended and Restated Certificate of Incorporation filed with the
Secretary of State of Delaware on July 2, 1998.(4)3.6
    
    Certificate of Increase of Series A Junior Participating Preferred Stock filed with the
Secretary of State of Delaware on July 2, 1998.(4)3.7
    
    Certificate of Amendment of Amended and Restated Certificate of Incorporation filed with the
Secretary of State of Delaware on November 12, 1998.(5)3.8
    
    Certificate of Designations of the Series S and Series S-1 Preferred Stock filed with the
Secretary of State of Delaware on June 29, 1999.(6)3.9
    
    Certificate of Amendment of Amended and Restated Certificate of Incorporation filed with the
Secretary of State of Delaware on July 1, 1999.(7)3.10
    
    Certificate of Amendment of Amended and Restated Certificate of Incorporation filed with the
Secretary of State of Delaware on September 23, 1999.(8)3.11
    
    Certificate of Decrease of Series A Junior Participating Preferred Stock filed with the
Secretary of State of Delaware on September 23, 1999.(8)3.12
    
    Certificate of Amendment of Amended and Restated Certificate of Incorporation filed with the
Secretary of State of Delaware on June 17, 2004.(9)3.13
    
    Certificate of Amendment of Amended and Restated Certificate of Incorporation filed with the
Secretary of State of Delaware on August 15, 2006.(10)3.14
    
    Certificate of Ownership and Merger, filed with the Secretary of State of Delaware on
August 15, 2006.(10)3.15
    
    Amended and Restated Bylaws of the Company. (11)4.1
    
    Reference is made to Exhibits 3.1 through 3.15.4.2
    
    Specimen certificate of the Common Stock.(12)10.64
    
    Amendment to Employment Agreement with Jean Loup Romet-Lemmone, dated July 16, 2007. (*) (14)10.65
    
    Employment Agreement with Jeffrey W. Sherman, dated August 27, 2007. (*)
 49




---



##### Table of Contents



ExhibitNumber
    
    Document Description31.1
    
    Certification of Principal Executive Officer pursuant to Section 302 of the Public Company
Accounting Reform and Investor Protection Act of 2002 (18 U.S.C. § 1350, as adopted).31.2
    
    Certification of Principal Financial Officer pursuant to Section 302 of the Public Company
Accounting Reform and Investor Protection Act of 2002 (18 U.S.C. § 1350, as adopted).32.1
    
    Certification pursuant to Section 906 of the Public Company Accounting Reform and Investor
Protection Act of 2002 (18 U.S.C. § 1350, as adopted).
 
 *
    
    Executive Compensation Plans and Arrangements(1)
    
    Incorporated by reference to the Companys Form S-1 Registration Statement and Amendments thereto filed
with Securities and Exchange Commission (the SEC) (File No. 33-43356).(2)
    
    Incorporated by reference to the Companys Form 8-K, filed with the SEC on March 22, 1993.(3)
    
    Incorporated by reference to the Companys Annual Report on Form 10-K for the fiscal year ended
December 31, 1994, filed with the SEC on March 31, 1995.(4)
    
    Incorporated by reference to the Companys Quarterly Report on Form 10-Q for the quarterly period ended
June 30, 1998, filed with the SEC on August 14, 1998.(5)
    
    Incorporated by reference to the Companys Quarterly Report on Form 10-Q for the quarterly period ended
September 30, 1998, filed with the SEC on November 16, 1998.(6)
    
    Incorporated by reference to the Companys Form 8-K, filed with the SEC on July 16, 1999.(7)
    
    Incorporated by reference to the Companys Definitive Proxy Statement, filed with the SEC on Form DEF 14A
on July 28, 1999.(8)
    
    Incorporated by reference to the Companys Quarterly Report on Form 10-Q for the quarterly period ended
September 30, 1999, filed with the SEC on November 15, 1999.(9)
    
    Incorporated by reference to the Companys Registration Statement on Form S-8, filed with the SEC on
July 2, 2004.(10)
    
    Incorporated by reference to the Companys Current Report on Form 8-K, filed with the SEC on August 17,
2006.(11)
    
    Incorporated by reference to the Companys Current Report on Form 8-K, filed on March 27, 2007.(12)
    
    Incorporated by reference to the Companys Definitive Proxy Statement on Form DEFM14A, filed with the SEC
on June 30, 2006.(13)
    
    Incorporated by reference to the Companys Current Report on Form 8-K, filed with the SEC on May 29, 2007.(14)
    
    Incorporated by reference to the Companys Quarterly Report on Form 10-Q for the quarterly period ended
June 30, 2007, filed with the SEC on August 10, 2007. 50




---



##### Table of Contents



IDM PHARMA, INC.
 
 SIGNATURES
  IDM PHARMA, INC.Dated: November 9, 2007
    By:
    /s/ Timothy P. WalbertTimothy P. WalbertPresident and Chief Executive Officer
(Principal Executive Officer)Dated: November 9, 2007
    By:
    /s/ Robert J. De VaereRobert J. De VaereSenior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) 51